Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday announced progress in preparing for its OBA Phase 2 trial of BIO101 for muscle wasting associated with obesity, securing non-dilutive funding from EMBRAPII, Brazil's government-backed innovation agency.

This support reduces cash requirements and underscores the programme's national significance.

Through its Brazilian subsidiary, Biophytis has also signed agreements with FARMAVAX-UFMG at the Federal University of Minas Gerais and FMRP-USP at the University of São Paulo. Both centres bring clinical expertise in obesity and metabolic disorders, large patient pools, and advanced research infrastructure.

Brazil is expected to recruit 122 of the trial's 164 patients, making it central to generating robust clinical data for BIO101. These partnerships strengthen recruitment capacity and ensure high-quality trial execution.

Meanwhile, Biophytis is finalising agreements with additional European sites, pursuing regulatory approvals from ANVISA and EMA, and preparing to begin patient enrolment in both regions. The company aims to move toward first patient dosing in the near term.